Literature DB >> 952568

Comparison of ancrod and heparin as anticoagulants following endarterectomy in the dog.

T M Daniel, S V Pizzo, P A Mckee.   

Abstract

An experimental model of surgically-induced arterial thrombosis was devised using the femoral arteries of dogs. Within 7 days, 67% of the arteries became completely thrombosed and only 12% remained compeletly patent. In the group of dogs that received low-dose heparin, 69% of the vessels were completely thrombosed and 6% remained completely patent. In the group of dogs treated with low-dose Ancrod to induce partial defibrination, 75% remained completely patent while only 19% of their femoral arteries were completely thrombosed. Although the ancrod was effective in preventing arterial thrombosis, 88% of the wounds showed moderate to severe separations. Most likely the absence of a fibrin lattice, necessary for the securement and growth of fibroblasts as the wound heals, explains this latter effect. Thus while Ancrod may become useful as an anticoagulant in certain clinical situations, it should not be used in proximity to surgery. Finally, in these studies of acute arterial thromboses, low-dose heparin therapy offered no protective effect.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 952568      PMCID: PMC1344435          DOI: 10.1097/00000658-197608000-00015

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  17 in total

1.  Platelet physiology and abnormalities of platelet function (first of two parts).

Authors:  H J Weiss
Journal:  N Engl J Med       Date:  1975-09-11       Impact factor: 91.245

Review 2.  Cross-linking of fibrin by fibrin=stabilizing factor.

Authors:  P A McKee; M L Schwartz; S V Pizzo; R L Hill
Journal:  Ann N Y Acad Sci       Date:  1972-12-08       Impact factor: 5.691

Review 3.  Theory and practice of minidose heparin in surgical patients. A status report.

Authors:  S Wessler; E T Yin
Journal:  Circulation       Date:  1973-04       Impact factor: 29.690

4.  Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin.

Authors:  S V Pizzo; M L Schwartz; R L Hill; P A McKee
Journal:  J Clin Invest       Date:  1972-11       Impact factor: 14.808

5.  Therapeutic defibrination in the treatment of thrombotic disease.

Authors:  W R Bell; W R Pitney; J F Goodwin
Journal:  Lancet       Date:  1968-03-09       Impact factor: 79.321

6.  Heparin action.

Authors:  R D Rosenberg
Journal:  Circulation       Date:  1974-04       Impact factor: 29.690

7.  Prevention of acute experimental arterial thrombosis by defibrination.

Authors:  M Haimov; C Danese
Journal:  Vasc Surg       Date:  1973 Sep-Oct

8.  Postsurgical hemorrhage in dogs anticoagulated with ancrod (Arvin).

Authors:  C L Slade; L M Taylor; A S Wechsler; P A McKee
Journal:  Ann Surg       Date:  1973-12       Impact factor: 12.969

9.  Inhibition of human factor IXa by human antithrombin.

Authors:  J S Rosenberg; P W McKenna; R D Rosenberg
Journal:  J Biol Chem       Date:  1975-12-10       Impact factor: 5.157

10.  Cross-linking of cold-insoluble globulin by fibrin-stabilizing factor.

Authors:  D F Mosher
Journal:  J Biol Chem       Date:  1975-08-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.